Financial savings

Novo Nordisk to Cut 9,000 Jobs Globally as New CEO Targets $1.3B Savings by 2026

1 week ago talkbio0Tagged CEO, competition, Doustdar, eli lilly, Financial cost, Financial savings, layoffs, Nordisk, Ozempic, profit guidance, restructuring, Wegovy, Weight-Loss Agents

Novo Nordisk; layoffs; 9000 jobs; cost savings; CEO Doustdar; restructuring; weight-loss drugs; Wegovy; Ozempic; competition; Eli Lilly; profit guidance

Sarepta Pursues Efficiency Measures Amid $1 Billion Debt Due in 2027

1 month ago talkbio0Tagged 2025, debt, decline, Efficiency, ELEVIDYS, Financial cost, financial results, Financial savings, Measures, Muscular Dystrophy, Duchenne, restructuring, United States Food and Drug Administration

Sarepta Therapeutics; debt 2027; efficiency measures; ELEVIDYS; cost savings; restructuring; financial results 2025; FDA; Duchenne muscular dystrophy; stock decline

Moderna to Cut 10% of Workforce in $1.5B Cost-Saving Push

2 months ago talkbio0Tagged Biotechnology, COVID-19 Vaccines, Financial savings, layoffs, Moderna, Stéphane Bancel

Moderna; layoffs; workforce reduction; cost-cutting; $1.5 billion savings; 2025; Stéphane Bancel; biotechnology; COVID-19 vaccine

Merck & Co. Targets $3B in Cost Savings Through Restructuring, Including Job Cuts

2 months ago talkbio0Tagged cost-cutting, Financial savings, Investments, Manufacturing, Merck & Co., R&D, restructuring, restructuring charges, Target

Merck & Co.; cost-cutting; $3 billion savings; restructuring; job cuts; 2027 target; restructuring charges; R&D; manufacturing investments

Keros Therapeutics Halts Pulmonary Hypertension Drug After Safety Issues, Cuts 45% of Workforce

4 months ago talkbio0Tagged biotech sector, cibotercept, drug development halt, Financial cost, Financial savings, layoffs, PAH, Pericardial effusion, Pulmonary arterial hypertension

Keros Therapeutics; cibotercept; pulmonary arterial hypertension; PAH; layoffs; pericardial effusion; drug development halt; cost savings; biotech sector

Teva plots thousands of job cuts as restructuring drive enters ‘acceleration’ phase

4 months ago talkbio0Tagged 8, Biological Factors, Financial cost, Financial savings, generics, Investments, Operational streamlining, Pivot Device, R&D, Strategic Overhaul, Workforce reduction

Workforce reduction (8%), $700 million cost savings, Strategic overhaul, Generics to biopharmaceuticals pivot, Operational streamlining, R&D investment